GE HealthCare Announces Availability of Next-Generation bkActiv for Guiding Urology, Colorectal and Pelvic Floor Surgeries

GE HealthCare (Nasdaq: GEHC) announced today the next-generation bkActiv is now available for guiding urology, colorectal and pelvic floor surgical procedures. The flagship intraoperative ultrasound imaging system, developed by BK Medical – a subsidiary of GE HealthCare, was designed to deliver high-performance ultrasound guidance with a simplified, intuitive user experience for surgeons. The bkActiv’s automatic no-touch autogain and advanced algorithms provide unmatched image quality, enabling confident decision making during surgical procedures. The system allows for minimal user interaction so that surgeons can focus on their patients.

“By expanding the bkActiv system, we are giving physicians the tools they need to provide precise treatment with the ability to see fine details in image guidance, which ultimately may allow for better outcomes for people who require urology, colorectal and pelvic floor procedures,” said Urvi Vyas, General Manager, Surgical Visualization & Guidance, Ultrasound at GE HealthCare, “We are proud to be the trusted partner for surgeons around the world given our long history of leadership in imaging and innovation.”

The bkActiv is a high-performance imaging system that allows for detailed, real-time surgical visualization, refined through decades of research, real-world use, and extensive user feedback. With this addition, the bkActiv now supports next level image quality of the prostate, kidney, and bladder, and has sensitive color doppler to visualize and measure the speed and direction of blood flow during the most complex surgical procedures. Combined with the new advanced portfolio of specialized, sterilizable transducers, needle guides, and procedure packs, the solution is designed to assist surgeons from simple procedures, such as biopsies, to the most advanced robotic surgeries.

The system’s features are designed with the physician in mind, and include:

  • Intuitive design with True-Sense touch technology and Smart Button that allow surgeons to operate the system with one hand for full control during the procedure
  • Advanced transducer portfolio including robotic and laparoscopic transducers
  • Adjustable monitor mounted on a flexible arm that allows for optimal image viewing with landscape or portrait mode
  • Easy integration into a crowded operating room due to its minimal system footprint

With the acquisition of BK Medical in 2021, GE HealthCare adds the fast-growing field of real-time surgical visualization to its pre- and post-operative ultrasound capabilities, creating an end-to-end offering through the full continuum of care. GE HealthCare has a long history of ultrasound innovation and a successful track record of growing technology acquisitions.

For more information on the bkActiv system for Urology visit:

For more information on the bkActiv system for Colorectal Surgery visit:

Medical Device News Magazine
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Data from clinical studies of STK-001 demonstrated clinical benefit for patients ages 2 to 18 years old, including reductions in seizures and improvements in cognition and behavior that support the potential for disease modificatio. Analysis of 72 patients treated in STK-001 clinical trials suggests that higher STK-001 drug exposure in brain leads to greater seizure reductions. Two-year data from the longest prospective natural history study of Dravet syndrome showed that, on average, patients experienced no meaningful improvement in convulsive seizure frequency and exhibited widening gaps in cognition and behavior despite treatment with the best available anti-seizure medicines.
"Exact Sciences is looking forward to presenting new evidence at SABCS that adds important perspectives to treating breast cancer patients and showing that some patients may be able to de-escalate treatments and still have positive outcomes," said Dr. Rick Baehner, Chief Medical Officer, Precision Oncology, Exact Sciences. "Every year, we build upon the precedent set by the Oncotype DX Breast Recurrence Score® test and its prognostic and predictive abilities to determine the chemotherapy benefit for specific breast cancer patients. We are pleased to see authorities expanding access to this test as we continue to develop key evidence in collaboration with some of the world's most prestigious, breast cancer-focused organizations."
Clozapine has been established as the most effective antipsychotic medication for treatment-resistant schizophrenia. However, it is significantly underutilized mainly due to the risk of developing agranulocytosis and the need to frequently monitor the absolute neutrophil count (ANC).
Dagi-Ben Noon, CEO of Inspira Technologies, reflects on the partnership's significance: "By Integrating our technology to oxygenate blood directly with Ennocure's infection prevention solutions, we are focusing on potentially improving patient outcomes in ICUs and paving the way for safer, more effective life-support treatments. This collaboration is expected to accelerate the development and broaden the implementation of our advanced technology."
The findings suggest that the novel, non-invasive genomic test can help physicians guide next steps for these patients, enabling them to potentially avoid unnecessary invasive procedures or accelerate time to appropriate treatment.

By using this website you agree to accept Medical Device News Magazine Privacy Policy